Welcome to our dedicated page for Abbvie news (Ticker: ABBV), a resource for investors and traders seeking the latest updates and insights on Abbvie stock.
AbbVie Inc. (NYSE: ABBV) is a pharmaceutical preparation manufacturing company that regularly issues news on its medicines, research programs, collaborations and manufacturing plans. Company communications emphasize a mission to discover and deliver medicines and solutions in key therapeutic areas such as immunology, oncology, neuroscience and eye care, as well as offerings in its Allergan Aesthetics portfolio.
News about AbbVie often covers clinical and scientific developments, particularly in oncology and blood cancers. The company has reported new data at major medical meetings, including results for investigational agents like etentamig (ABBV‑383) and PVEK, and updates on approved medicines such as EPKINLY (epcoritamab-bysp) and VENCLEXTA (venetoclax). Releases may detail trial outcomes, regulatory milestones, and additional indications under investigation.
Investors and observers can also find corporate and financial updates in AbbVie’s news flow, including announcements of earnings conference calls, participation in healthcare and investor conferences, and guidance-related information that aligns with its SEC filings. The company additionally highlights strategic agreements and collaborations, such as its exclusive licensing agreement with RemeGen for the PD‑1/VEGF bispecific antibody RC148 and its voluntary agreement with the U.S. administration focused on access, affordability and U.S.-based investment.
Another recurring theme in AbbVie’s news is manufacturing and investment activity. The company has announced a definitive agreement to acquire a device manufacturing facility in Tempe, Arizona, to expand drug delivery device manufacturing for immunology and neuroscience medicines, and has referenced multi‑year commitments to U.S. R&D and capital investments. AbbVie also publishes stories on patient- and community-focused initiatives, such as the “Second Winds” film about people living with chronic lymphocytic leukemia. For readers tracking ABBV, this news stream provides insight into the company’s research pipeline, regulatory progress, capital allocation and patient engagement efforts.
AbbVie (NYSE: ABBV) announced positive topline Phase 1 multiple ascending dose results for ABBV-295 on March 9, 2026. ABBV-295, a long-acting amylin analog, produced dose-dependent mean weight reductions of -7.75% to -9.79% at week 12 (weekly dosing) and -7.86% to -9.73% at week 13 (alternate dosing), versus placebo ~-0.25%.
The study tested 2–14 mg doses, enrolled mostly male participants (88.3%), showed a favorable tolerability profile with no serious adverse events, and reported mostly mild gastrointestinal events early in treatment. Full data will be presented at a future scientific conference.
Allergan Aesthetics (NYSE:ABBV) released data on March 4, 2026 showing Medical Weight Loss (MWL) is reshaping aesthetic demand, with patients prioritizing facial appearance and volume restoration.
Key metrics: 67% changed goals toward appearance, 61% report midface volume loss, 81% of HCPs favor HA fillers, and 60% of GLP-1 users obtain medications from providers who also offer aesthetic services (up from 49%).
AbbVie (NYSE: ABBV) will participate in the Leerink Partners Global Healthcare Conference on Tuesday, March 10, 2026. Management will take part in a fireside chat at 10:20 a.m. Central Time. A live audio webcast will be available via AbbVie's Investor Relations site, with an archived edition posted later that day.
AbbVie (NYSE: ABBV) reported positive topline results from the Phase 3 AFFIRM study of risankizumab (SKYRIZI) subcutaneous induction in adults with moderately to severely active Crohn's disease on March 2, 2026. Co-primary endpoints at week 12 met: CDAI clinical remission 55% vs 30% and endoscopic response 44% vs 14% versus placebo (both p<0.0001). Among 12-week responders who continued maintenance, 67% achieved clinical remission and 57% achieved endoscopic response at week 24. Safety was consistent with known profile; most common adverse events were upper respiratory tract infection, abdominal pain and arthralgia.
AbbVie (NYSE: ABBV) will present at the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3, 2026. Management will take part in a fireside chat at 10:10 a.m. Central Time. A live audio webcast and an archived edition will be available via AbbVie's investor site.
AbbVie (NYSE: ABBV) will invest $380 million to build two new active pharmaceutical ingredient (API) facilities at its North Chicago campus, supporting next-generation neuroscience and obesity medicines. Construction starts spring 2026 and both facilities are expected to be fully operational in 2029.
The project will add advanced manufacturing and AI integration and is expected to create 300 jobs in engineering, science and operations, and is part of AbbVie's broader $100 billion U.S. R&D and capital commitment over the next decade.
AbbVie (NYSE: ABBV) announced FDA approval of the combination of VENCLEXTA (venetoclax) and acalabrutinib for previously untreated adult patients with chronic lymphocytic leukemia (CLL) on Feb 20, 2026.
The approval, supported by data from the Phase 3 AMPLIFY trial, establishes the first all-oral, fixed-duration regimen in the first-line CLL setting and offers a time-limited treatment option for patients and providers.
AbbVie (NYSE: ABBV) declared a quarterly cash dividend of $1.73 per share, payable May 15, 2026, to holders of record at the close of business on April 15, 2026.
Since 2013 AbbVie has increased its dividend by more than 330% and remains a member of the S&P Dividend Aristocrats Index.
AbbVie (NYSE:ABBV) reported full-year 2025 net revenues of $61.160 billion (+8.6% reported, +8.5% operational) and full-year GAAP diluted EPS of $2.36 (adjusted diluted EPS $10.00), which include an unfavorable $2.76 per-share impact from acquired IPR&D and milestones. Fourth-quarter revenues were $16.618 billion (+10.0% reported) with adjusted diluted EPS of $2.71 and GAAP EPS of $1.02. AbbVie provided 2026 adjusted diluted EPS guidance of $14.37–$14.57, excluding any acquired IPR&D and milestones impact.
Key portfolio highlights: Skyrizi $17.562B, Rinvoq $8.304B, Humira $4.540B; 2025 saw multiple regulatory submissions and an FDA approval for Epkinly in follicular lymphoma.
Allergan Aesthetics (NYSE: ABBV) launched the Faces of Natrelle® Testimonial Program on Feb 3, 2026, inviting U.S. women who had Natrelle® breast augmentation or reconstruction at age 22+ to submit photos, videos, and testimonials for possible publication.
Augmentation participants who are Allē members may receive five $100 Allē gift cards if selected and approved; reconstruction patients are encouraged to share but are not eligible for compensation. Important safety information and a Boxed Warning for breast implants are reiterated, including BIA-ALCL risk and recommended imaging timelines.